{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T09:14:41Z","timestamp":1783502081979,"version":"3.55.0"},"reference-count":65,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Oral and Maxillofacial Surgery Clinics of North America"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.coms.2021.11.010","type":"journal-article","created":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T19:07:42Z","timestamp":1651172862000},"page":"315-324","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Adjuvant and Neoadjuvant Therapies in Cutaneous Melanoma"],"prefix":"10.1016","volume":"34","author":[{"given":"Jay","family":"Ponto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Bryan","family":"Bell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coms.2021.11.010_bib1","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1002\/cncr.32802","article-title":"Annual report to the nation on the status of cancer, part I: national cancer statistics","volume":"126","author":"Henley","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.coms.2021.11.010_bib2","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1200\/JCO.2007.12.7837","article-title":"Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials","volume":"26","author":"Korn","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.coms.2021.11.010_bib3","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1056\/NEJMra2034861","article-title":"Recent Advances in the Treatment of Melanoma","volume":"384","author":"Curti","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.coms.2021.11.010_bib4","first-page":"472","article-title":"Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual","volume":"67","author":"Gershenwald","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.coms.2021.11.010_bib5","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/jamadermatol.2020.1731","article-title":"Performance of gene expression profile tests for prognosis in patients with localized cutaneous melanoma: a systematic review and meta-analysis","volume":"156","author":"Marchetti","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.coms.2021.11.010_bib6","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.2217\/fon-2018-0912","article-title":"Guidance of sentinel lymph node biopsy decisions in patients with T1-T2 melanoma using gene expression profiling","volume":"15","author":"Vetto","year":"2019","journal-title":"Future Oncol"},{"key":"10.1016\/j.coms.2021.11.010_bib7","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ejca.2020.08.029","article-title":"Identification of stage I\/IIA melanoma patients at high risk for disease relapse using a clinicopathologic and gene expression model","volume":"140","author":"Eggermont","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.coms.2021.11.010_bib8","doi-asserted-by":"crossref","first-page":"8498","DOI":"10.1002\/cam4.3481","article-title":"Integrated genomic analysis identifies a genetic mutation model predicting response to immune checkpoint inhibitors in melanoma","volume":"9","author":"Jiang","year":"2020","journal-title":"Cancer Med"},{"key":"10.1016\/j.coms.2021.11.010_bib9","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.coms.2021.11.010_bib10","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1056\/NEJM198512053132327","article-title":"Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer","volume":"313","author":"Rosenberg","year":"1985","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.coms.2021.11.010_bib11","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.1999.17.7.2105","article-title":"High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993","volume":"17","author":"Atkins","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.coms.2021.11.010_bib12","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1136\/jim-2020-001650","article-title":"Long-term progression-free survival of patients with metastatic melanoma or renal cell carcinoma following high-dose interleukin-2","volume":"69","author":"Clark","year":"2021","journal-title":"J Investig Med."},{"key":"10.1016\/j.coms.2021.11.010_bib13","article-title":"Randomized phase II study of stereotactic body radiotherapy and interleukin-2 versus interleukin-2 in patients with metastatic melanoma","volume":"8","author":"Curti","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.coms.2021.11.010_bib14","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/2051-1426-2-13","article-title":"Durable responses and reversible toxicity of high-dose interleukin-2 treatment of melanoma and renal cancer in a Community Hospital Biotherapy Program","volume":"2","author":"Payne","year":"2014","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.coms.2021.11.010_bib15","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/328267a0","article-title":"A\u00a0new member of the immunoglobulin superfamily--CTLA-4","volume":"328","author":"Brunet","year":"1987","journal-title":"Nature"},{"key":"10.1016\/j.coms.2021.11.010_bib16","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","article-title":"Enhancement of antitumor immunity by CTLA-4 blockade","volume":"271","author":"Leach","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.coms.2021.11.010_bib17","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1084\/jem.182.2.459","article-title":"CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation","volume":"182","author":"Krummel","year":"1995","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.coms.2021.11.010_bib18","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.coms.2021.11.010_bib19","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","article-title":"Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma","volume":"33","author":"Schadendorf","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.coms.2021.11.010_bib20","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","article-title":"Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death","volume":"11","author":"Ishida","year":"1992","journal-title":"EMBO J"},{"key":"10.1016\/j.coms.2021.11.010_bib21","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1074-7613(00)80089-8","article-title":"Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor","volume":"11","author":"Nishimura","year":"1999","journal-title":"Immunity"},{"key":"10.1016\/j.coms.2021.11.010_bib22","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.coms.2021.11.010_bib23","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.coms.2021.11.010_bib24","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/S1470-2045(18)30700-9","article-title":"Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial","volume":"19","author":"Hodi","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.coms.2021.11.010_bib25","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(17)31601-X","article-title":"Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)","volume":"390","author":"Schachter","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.coms.2021.11.010_bib26","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus ipilimumab in advanced melanoma","volume":"369","author":"Wolchok","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.coms.2021.11.010_bib27","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1200\/JCO.2017.72.2850","article-title":"Nivolumab plus ipilimumab in patients with advanced melanoma: updated survival, response, and safety data in a phase I dose-escalation study","volume":"36","author":"Callahan","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.coms.2021.11.010_bib28","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.coms.2021.11.010_bib29","unstructured":"melanoma. TCGANGcoc, 1681-1696. C."},{"key":"10.1016\/j.coms.2021.11.010_bib30","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.coms.2021.11.010_bib31","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","article-title":"Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma","volume":"371","author":"Long","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.coms.2021.11.010_bib32","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1093\/annonc\/mdx176","article-title":"Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E\/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study","volume":"28","author":"Long","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.coms.2021.11.010_bib33","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S1470-2045(12)70269-3","article-title":"Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial","volume":"13","author":"Falchook","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.coms.2021.11.010_bib34","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJMoa1904059","article-title":"Five-Year outcomes with dabrafenib plus trametinib in metastatic melanoma","volume":"381","author":"Robert","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.coms.2021.11.010_bib35","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/S1470-2045(18)30497-2","article-title":"Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial","volume":"19","author":"Dummer","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.coms.2021.11.010_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2019.07.001","article-title":"Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial","volume":"119","author":"Eggermont","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.coms.2021.11.010_bib37","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S1470-2045(18)30142-6","article-title":"Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial","volume":"19","author":"Dummer","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.coms.2021.11.010_bib38","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/S1470-2045(16)30122-X","article-title":"Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial","volume":"17","author":"Ascierto","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.coms.2021.11.010_bib39","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11111642","article-title":"Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for BRAF-Mutant Melanoma","volume":"11","author":"Hamid","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.coms.2021.11.010_bib40","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1200\/JCO.2000.18.12.2444","article-title":"High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690\/S9111\/C9190","volume":"18","author":"Kirkwood","year":"2000","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.coms.2021.11.010_bib41","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(08)61033-8","article-title":"Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial","volume":"372","author":"Eggermont","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.coms.2021.11.010_bib42","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1056\/NEJMoa1611299","article-title":"Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy","volume":"375","author":"Eggermont","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.coms.2021.11.010_bib43","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1200\/JCO.19.01381","article-title":"Phase III study of adjuvant ipilimumab (3 or 10 mg\/kg) versus high-dose interferon Alfa-2b for resected high-risk melanoma: North American Intergroup E1609","volume":"38","author":"Tarhini","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.coms.2021.11.010_bib44","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/S1470-2045(20)30494-0","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial","volume":"21","author":"Ascierto","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.coms.2021.11.010_bib45","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S1470-2045(21)00065-6","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG\/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial","volume":"22","author":"Eggermont","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.coms.2021.11.010_bib46","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S0140-6736(20)30417-7","article-title":"Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"395","author":"Zimmer","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.coms.2021.11.010_bib47","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma","volume":"377","author":"Long","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.coms.2021.11.010_bib48","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa2005493","article-title":"Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma","volume":"383","author":"Dummer","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 5. Abstract LBA3_PR","key":"10.1016\/j.coms.2021.11.010_bib49","article-title":"Pembrolizumab versus placebo after complete resection of high-risk stage II melanoma: efficacy and safety results from the KEYNOTE-716 double-blind phase III trial","volume":"32","author":"Luke","year":"2021","journal-title":"Ann Oncol (ESMO Congress Abstracts)"},{"key":"10.1016\/j.coms.2021.11.010_bib50","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1158\/2159-8290.CD-16-0577","article-title":"Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease","volume":"6","author":"Liu","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1016\/j.coms.2021.11.010_bib51","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41591-019-0357-y","article-title":"A\u00a0single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma","volume":"25","author":"Huang","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.coms.2021.11.010_bib52","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ejca.2021.04.035","article-title":"Neoadjuvant immunotherapy is reshaping cancer management across multiple tumour types: the future is now","volume":"152","author":"Maio","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.coms.2021.11.010_bib53","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/CMR.0000000000000214","article-title":"BRAF inhibition for advanced locoregional BRAF V600E mutant melanoma: a potential neoadjuvant strategy","volume":"26","author":"Sloot","year":"2016","journal-title":"Melanoma Res"},{"key":"10.1016\/j.coms.2021.11.010_bib54","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1038\/s41591-018-0197-1","article-title":"Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma","volume":"24","author":"Amaria","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.coms.2021.11.010_bib55","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1038\/s41591-018-0198-0","article-title":"Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma","volume":"24","author":"Blank","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.coms.2021.11.010_bib56","doi-asserted-by":"crossref","first-page":"MMT27","DOI":"10.2217\/mmt-2019-0007","article-title":"The emergence of neoadjuvant therapy in advanced melanoma","volume":"6","author":"Sun","year":"2019","journal-title":"Melanoma Manag"},{"key":"10.1016\/j.coms.2021.11.010_bib57","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1470-2045(18)30015-9","article-title":"Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial","volume":"19","author":"Amaria","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.coms.2021.11.010_bib58","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/S1470-2045(19)30151-2","article-title":"Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial","volume":"20","author":"Rozeman","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.coms.2021.11.010_bib59","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/s41591-020-01211-7","article-title":"Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma","volume":"27","author":"Rozeman","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.coms.2021.11.010_bib60","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41591-020-01188-3","article-title":"Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)","volume":"27","author":"Menzies","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.coms.2021.11.010_bib61","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1038\/s41591-021-01398-3","article-title":"An ex\u00a0vivo tumor fragment platform to dissect response to PD-1 blockade in cancer","volume":"27","author":"Voabil","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.coms.2021.11.010_bib62","doi-asserted-by":"crossref","first-page":"611365","DOI":"10.3389\/fonc.2021.611365","article-title":"Explant Modeling of the Immune Environment of Head and Neck Cancer","volume":"11","author":"Sharon","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.coms.2021.11.010_bib63","first-page":"205","article-title":"In\u00a0vivo sensitivity of human melanoma to tumor necrosis factor (TNF)-alpha is determined by tumor production of the novel cytokine endothelial-monocyte activating polypeptide II (EMAPII)","volume":"59","author":"Wu","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.coms.2021.11.010_bib64","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1002\/ijc.29515","article-title":"TLR2\/6 agonists and interferon-gamma induce human melanoma cells to produce CXCL10","volume":"137","author":"Mauldin","year":"2015","journal-title":"Int J Cancer"},{"key":"10.1016\/j.coms.2021.11.010_bib65","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1007\/s00262-016-1881-y","article-title":"Intratumoral interferon-gamma increases chemokine production but fails to increase T cell infiltration of human melanoma metastases","volume":"65","author":"Mauldin","year":"2016","journal-title":"Cancer Immunol Immunother"}],"container-title":["Oral and Maxillofacial Surgery Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1042369921001138?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1042369921001138?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T20:14:19Z","timestamp":1760904859000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1042369921001138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":65,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S1042369921001138"],"URL":"https:\/\/doi.org\/10.1016\/j.coms.2021.11.010","relation":{},"ISSN":["1042-3699"],"issn-type":[{"value":"1042-3699","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adjuvant and Neoadjuvant Therapies in Cutaneous Melanoma","name":"articletitle","label":"Article Title"},{"value":"Oral and Maxillofacial Surgery Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coms.2021.11.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}